Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
Authors:
- Ilaria Grazia ZizzariIZIlaria Grazia Zizzari
- Chiara NapoletanoCNChiara Napoletano
- Alessandra Di FilippoAFAlessandra Di Filippo
- Andrea BotticelliABAndrea Botticelli
- Alain GelibterAGAlain Gelibter
- Fabio CalabròFCFabio Calabrò
- Ernesto RossiERErnesto Rossi
- Giovanni SchinzariGSGiovanni Schinzari
- Federica UrbanoFUFederica Urbano
- Giulia PomatiGPGiulia Pomati
- Simone ScagnoliSSSimone Scagnoli
- Aurelia RughettiARAurelia Rughetti
Open Access
Abstract
With the introduction of immune checkpoint inhibitors (ICIs) and next-generation vascular endothelial growth factor receptor–tyrosine kinase inhibitors (VEGFR–TKIs), the survival of patients with advanced renal cell carcinoma (RCC) has improved remarkably. However, not all patients have benefited from treatments, and to date, there are still no validated biomarkers that can be included in the therapeutic algorithm. Thus, the identification of predictive biomarkers is necessary to increase the number of responsive patients and to understand the underlying immunity. The clinical outcome of RCC patients is, in fact, associated with immune response. In this exploratory pilot study, we assessed the immune effect of TKI therapy in order to evaluate the immune status of metastatic renal cell carcinoma (mRCC) patients so that we could define a combination of immunological biomarkers relevant to improving patient outcomes. We profiled the circulating levels in 20 mRCC patients of exhausted/activated/regulatory T cell subsets through flow cytometry and of 14 immune checkpoint-related proteins and 20 inflammation cytokines/chemokines using multiplex Luminex assay, both at baseline and during TKI therapy. We identified the CD3+CD8+CD137+ and CD3+CD137+PD1+ T cell populations, as well as seven soluble immune molecules (i.e., IFNγ, sPDL2, sHVEM, sPD1, sGITR, sPDL1, and sCTLA4) associated with the clinical responses of mRCC patients, either modulated by TKI therapy or not. These results suggest an immunological profile of mRCC patients, which will help to improve clinical decision-making for RCC patients in terms of the best combination of strategies, as well as the optimal timing and therapeutic sequence.Keywords
Funding Information
- Sapienza Università di Roma (Ateneo MN 2016)
- Associazione Italiana per la Ricerca sul Cancro (MN:AIRC/2015)
This publication has 50 references indexed in Scilit:
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trialThe Lancet Oncology, 2013
- The presence of high level soluble herpes virus entry mediator in sera of gastric cancer patientsExperimental & Molecular Medicine, 2012
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer PatientsJournal of Immunotherapy, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytesBritish Journal of Cancer, 2009
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma PatientsClinical Cancer Research, 2008
- The role of positive costimulatory molecules in transplantation and toleranceCurrent Opinion in Organ Transplantation, 2008
- Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapiesTrends in Pharmacological Sciences, 2008
- Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificitiesBlood, 2007
- 4-1BB-mediated immunotherapy of rheumatoid arthritisNature Medicine, 2004